U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07403799) titled 'REal-life ON PARKinson's - ITaly (REONPARK-IT)' on Feb. 04.
Brief Summary: The present study aims to evaluate the effectiveness and safety of opicapone in a real-world setting at centers for Parkinson's disease located in Italy.
Study Start Date: July 08, 2025
Study Type: OBSERVATIONAL
Condition:
Parkinson Disease
Intervention:
DRUG: Opicapone 50 mg
The recommended dose of opicapone is 50 mg. Opicapone must be taken once a day before going to bed, at least one hour before or one hour after levodopa combinations. As opicapone enhances the effects of levodopa, it could be necessary to adjust levodopa dose by extending the dosin...